GaryPhilipSchwartzMD

Cardiology • Frederick, MD

Adult Congenital Heart Disease

Physician

Join to view full profile

Are you Dr. Schwartz?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Connect with colleagues in the same hospital or clinic
You already have 26 invites waiting!
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Office
6360 Claridge Dr N
Frederick, MD 21701
Phone+1 301-696-2826
Is this information wrong?

Summary

Dr. Gary Schwartz, MD is a cardiologist in Frederick, Maryland. He is currently licensed to practice medicine in Maryland, Virginia, and New Jersey.

Education & Training

Montefiore Medical Center/Albert Einstein College of Medicine (Montefiore)Fellowship, Cardiovascular Disease, 1972 - 1974
University of Michigan Health SystemResidency, Internal Medicine, 1970 - 1972
Icahn School of Medicine at Mount Sinai (Beth Israel)Residency, Internal Medicine, 1969 - 1970
Mount Sinai Beth Israel HospitalInternship, Transitional Year, 1968 - 1969
SUNY Upstate Medical UniversityClass of 1968

Certifications & Licensure

MD State Medical License 1974 - 2025
VA State Medical License 1996 - 2006
NJ State Medical License 1986 - 1993
PA State Medical License 1984 - 1984
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Cardiovascular Disease

Publications & Presentations

PubMed

A Right Atrial Mass: "More Than Meets the Eye".
Arora, V.,Schwartz, G.,Tilson, M. P.,Netto, G. J.,Mandal, K.> ;J. Clin. Oncol.. 2014 Jun 25
Comprehensive CYP2D6 genotyping in a multiracial population shows differences in allele frequencies between races.
Irvin WJ, Weck KE, Walko CM, Chiu WK, Rubin P, Olajide OA, Moore SG, Raab RE, Carrizosa DR, Corso SW, Schwartz G, Anderson SM, Friedman KJ, Dees EC, Flockhart D, Peppe...> ;J. Clin. Oncol.. 2011-05-20
Patients' understanding of how genotype variation affects benefits of tamoxifen therapy for breast cancer.
Brewer NT, Walko CM, Chiu WK, Dressler LG, Yuen A, Rubin P, Olajide OA, Moore SG, Raab RE, Carrizosa DR, Corso SW, Schwartz G, Peppercorn JM, McLeod HL, Carey LA, Irvi...> ;J. Clin. Oncol.. 2011-05-20
Oral paricalcitol (19-nor-1,25-Dihydroxyvitamn D2) in women with metastatic breast cancer receiving taxanes or ixabepilone: A feasibility trial.
Lawrence J, Lovelace J, Akman SA, Melin SA, Case LD, Schwartz G> ;J. Clin. Oncol.. 2011-05-20
Phase I/II trial of bevacizumab (B) and erlotinib (E) with induction (IND) and concurrent (CON) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic conformal radioth...
Stinchcombe T, Socinski MA, Moore DT, Gettinger SN, Decker RH, Petty WJ, Blackstock AW, Schwartz G, Lankford S, Morris DE> ;J. Clin. Oncol.. 2011-05-20
Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.
Burstein HJ, Sun Y, Dirix LY, Jiang Z, Paridaens R, Tan AR, Awada A, Ranade A, Jiao S, Schwartz G, Abbas R, Powell C, Turnbull K, Vermette J, Zacharchuk C, Badwe R> ;J. Clin. Oncol.. 2010-03-10
A putative tumor suppressor role for Wnt-signaling in sarcomagenesis.
Matushansky I, Socci N, Hernando E, Singer S, Schwartz G, Cordon-Cardo C, Maki R> ;J. Clin. Oncol.. 2006-06-20
A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of the combination of an oral antimicrotubular agent, DJ-927 (D), and capecitabine (C) in patients (Pts)...
Beeram M, Saif WM, Sarantopoulos J, Schwartz G, Patnaik A, Tolcher AW, Mehdi F, Feit K, Takimoto CH> ;J. Clin. Oncol.. 2006-06-20
Phase I evaluation of paclitaxel poliglumex (PPX) administered weekly for patients with advanced cancer.
Takimoto CH, Schwartz G, Romero O, Patnaik A, Tolcher A, Garrison M, Oldham FB, Bernareggi A, Rowinsky E> ;J. Clin. Oncol.. 2005-06-01
A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of the combination of an oral antimicrotubular agent, DJ-927 (D), and capecitabine (C) in patients (Pts)...
Beeram M, Saif MW, Sarantopoulos J, Schwartz G, Patnaik A, Tolcher AW, Cheverton P, Kimura M, Danna M, Takimoto CH> ;J. Clin. Oncol.. 2005-06-01
Phase I and pharmacokinetics (PK) of combined erbB1 and erbB2 blockade with OSI-774 (erlotinib; E) and trastuzumab (T) in combination with weekly paclitaxel (P) in pat...
Patnaik A, Beeram M, de Bono JS, Mita A, Chu SC, Rowinsky EK, Schwartz G, O'Rourke P, Takimoto CH, Tolcher AW> ;J. Clin. Oncol.. 2005-06-01
A pilot, pharmacokinetic (PK), and pharmacodynamic (PD) study to determine the feasibility of intrapatient dose escalation to tolerable rash and the activity of maxima...
Mita CA, Schwartz G, Mita MM, Papadopoulos K, Wood L, de Jonge M, Yancik S, Hamilton M, Santabarbara P, Rowinsky E> ;J. Clin. Oncol.. 2005-06-01
Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: A single-institution compilation compared with the National...
Morris GJ, Naidu S, Topham A, McCue P, Schwartz G, Rosenberg A, Mitchell EP> ;J. Clin. Oncol.. 2005-06-01
A phase I study of weekly irinotecan (CPT), cisplatin (CIS) and flavopiridol (F).
Shah MA, Kortmansky J, Gonen M, Tse A, Lefkowitz R, Kelsen D, Colevas D, Winkelman J, Yi S, Schwartz G> ;J. Clin. Oncol.. 2004-07-15
17-Allylamino-17-Demethoxygeldanamycin (17-AAG) abrogates the G2/M cell cycle checkpoint by down-regulating chk1 and selectively sensitizes tumor cells with defective ...
Tse AN, Solit D, Rosen N, Schwartz G> ;J. Clin. Oncol.. 2004-07-15
Phase I clinical, biology & pharmacokinetic study of the combination of GW 572016 and capecitabine in patients with advanced solid tumors.
Schwartz G, Chu QS, Hammond LA, Mita M, Curtright J, Versola MJ, Koch K, Pandite LN, Ho PTC, Rowinsky EK> ;J. Clin. Oncol.. 2004-07-15
Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties.
Tolcher AW, Eckhardt SG, Kuhn J, Hammond L, Weiss G, Rizzo J, Aylesworth C, Hidalgo M, Patnaik A, Schwartz G, Felton S, Campbell E, Rowinsky EK> ;J. Clin. Oncol.. 2001-06-01
Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel.
Hidalgo M, Aylesworth C, Hammond LA, Britten CD, Weiss G, Stephenson J, Schwartz G, Patnaik A, Smith L, Molpus K, Felton S, Gupta E, Ferrante KJ, Tortora A, Sonnichsen...> ;J. Clin. Oncol.. 2001-05-01
DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
Rowinsky EK, Johnson TR, Geyer CE, Hammond LA, Eckhardt SG, Drengler R, Smetzer L, Coyle J, Rizzo J, Schwartz G, Tolcher A, Von Hoff DD, De Jager RL> ;J. Clin. Oncol.. 2000-09-01
Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer.
Ilson DH, Saltz L, Enzinger P, Huang Y, Kornblith A, Gollub M, O'Reilly E, Schwartz G, DeGroff J, Gonzalez G, Kelsen DP> ;J. Clin. Oncol.. 1999-10-01
High-dose multimodality therapy with autologous stem-cell support for stage IIIB breast carcinoma.
Ayash LJ, Elias A, Ibrahim J, Schwartz G, Wheeler C, Reich E, Lynch C, Warren D, Shapiro C, Richardson P, Hurd D, Schnipper L, Frei E, Antman K> ;J. Clin. Oncol.. 1998-03-01
Phase I trial of PN401, an oral prodrug of uridine, to prevent toxicity from fluorouracil in patients with advanced cancer.
Kelsen DP, Martin D, O'Neil J, Schwartz G, Saltz L, Sung MT, von Borstel R, Bertino J> ;J. Clin. Oncol.. 1997-04-01
Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-...
Ayash LJ, Elias A, Schwartz G, Wheeler C, Ibrahim J, Teicher BA, Reich E, Warren D, Lynch C, Richardson P, Schnipper L, Frei E, Antman K> ;J. Clin. Oncol.. 1996-11-01
Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluor...
Kelsen D, Karpeh M, Schwartz G, Gerdes H, Lightdale C, Botet J, Lauers G, Klimstra D, Huang Y, Saltz L, Quan V, Brennan M> ;J. Clin. Oncol.. 1996-06-01
Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer.
Ayash LJ, Wheeler C, Fairclough D, Schwartz G, Reich E, Warren D, Schnipper L, Antman K, Frei E, Elias A> ;J. Clin. Oncol.. 1995-08-01
Join now to see all